Cannell & Spears’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $438K | Buy |
3,146
+6
| +0.2% | +$840 | 0.01% | 311 |
|
|
2025
Q4 | $385K | Sell |
3,140
-316
| -9% | -$38.4K | 0.01% | 322 |
|
|
2025
Q3 | $384K | Buy |
3,456
+53
| +2% | +$6.02K | 0.01% | 317 |
|
|
2025
Q2 | $377K | Buy |
3,403
+6
| +0.2% | +$639 | 0.01% | 311 |
|
|
2025
Q1 | $381K | Sell |
3,397
-680
| -17% | -$70.2K | 0.01% | 304 |
|
|
2024
Q4 | $377K | Sell |
4,077
-814
| -17% | -$73.3K | 0.01% | 314 |
|
|
2024
Q3 | $410K | Buy |
4,891
+666
| +16% | +$50.8K | 0.01% | 317 |
|
|
2024
Q2 | $290K | Hold |
4,225
| – | – | 0.01% | 311 |
|
|
2024
Q1 | $309K | Buy |
+4,225
| New | +$325K | 0.01% | 314 |
|
|
2021
Q4 | – | Sell |
-65,202
| Closed | -$4.55M | – | 236 |
|
|
2021
Q3 | $4.55M | Sell |
65,202
-450
| -0.7% | -$31.6K | 0.33% | 49 |
|
|
2021
Q2 | $4.52M | Sell |
65,652
-485
| -0.7% | -$32.4K | 0.32% | 49 |
|
|
2021
Q1 | $4.27M | Buy |
66,137
+269
| +0.4% | +$17.3K | 0.33% | 49 |
|
|
2020
Q4 | $3.84M | Sell |
65,868
-2,482
| -4% | -$150K | 0.32% | 50 |
|
|
2020
Q3 | $4.32M | Buy |
68,350
+800
| +1% | +$55.5K | 0.41% | 43 |
|
|
2020
Q2 | $5.2M | Sell |
67,550
-3,200
| -5% | -$245K | 0.55% | 34 |
|
|
2020
Q1 | $5.29M | Sell |
70,750
-317,380
| -82% | -$21.9M | 0.65% | 30 |
|
|
2019
Q4 | $25.2M | Buy |
388,130
+1,400
| +0.4% | +$91.2K | 2.7% | 15 |
|
|
2019
Q3 | $24.5M | Sell |
386,730
-2,530
| -0.6% | -$165K | 2.84% | 14 |
|
|
2019
Q2 | $26.3M | Buy |
389,260
+38,865
| +11% | +$2.56M | 3.09% | 12 |
|
|
2019
Q1 | $22.8M | Buy |
350,395
+52,519
| +18% | +$3.49M | 2.91% | 15 |
|
|
2018
Q4 | $18.6M | Sell |
297,876
-5,796
| -2% | -$405K | 2.73% | 16 |
|
|
2018
Q3 | $23.4M | Sell |
303,672
-4,001
| -1% | -$302K | 2.8% | 15 |
|
|
2018
Q2 | $21.8M | Sell |
307,673
-993
| -0.3% | -$70.1K | 2.83% | 16 |
|
|
2018
Q1 | $23.3M | Sell |
308,666
-4,789
| -2% | -$381K | 3.03% | 14 |
|
|
2017
Q4 | $22.5M | Sell |
313,455
-2,699
| -0.9% | -$205K | 2.73% | 16 |
|
|
2017
Q3 | $25.6M | Sell |
316,154
-3,910
| -1% | -$299K | 3.06% | 15 |
|
|
2017
Q2 | $22.7M | Sell |
320,064
-706
| -0.2% | -$47K | 2.82% | 18 |
|
|
2017
Q1 | $21.8M | Buy |
320,770
+157,752
| +97% | +$11.1M | 2.75% | 19 |
|
|
2016
Q4 | $11.7M | Sell |
163,018
-12,846
| -7% | -$955K | 1.5% | 25 |
|
|
2016
Q3 | $13.9M | Buy |
175,864
+84,857
| +93% | +$6.89M | 1.75% | 25 |
|
|
2016
Q2 | $7.59M | Sell |
91,007
-215
| -0.2% | -$19.1K | 0.96% | 25 |
|
|
2016
Q1 | $8.38M | Sell |
91,222
-1,380
| -1% | -$124K | 1.02% | 25 |
|
|
2015
Q4 | $9.37M | Sell |
92,602
-4,495
| -5% | -$468K | 1.07% | 24 |
|
|
2015
Q3 | $9.53M | Buy |
97,097
+515
| +0.5% | +$57.2K | 1.09% | 26 |
|
|
2015
Q2 | $11.3M | Sell |
96,582
-2,359
| -2% | -$258K | 1.25% | 24 |
|
|
2015
Q1 | $9.71M | Sell |
98,941
-1,280
| -1% | -$130K | 1.16% | 24 |
|
|
2014
Q4 | $9.45M | Sell |
100,221
-544
| -0.5% | -$56.3K | 1.05% | 29 |
|
|
2014
Q3 | $10.7M | Sell |
100,765
-5,549
| -5% | -$543K | 1.28% | 28 |
|
|
2014
Q2 | $8.81M | Sell |
106,314
-140,728
| -57% | -$11M | 1.04% | 29 |
|
|
2014
Q1 | $17.5M | Sell |
247,042
-10,533
| -4% | -$826K | 2.2% | 21 |
|
|
2013
Q4 | $19.3M | Buy |
257,575
+103,655
| +67% | +$7.22M | 2.41% | 22 |
|
|
2013
Q3 | $9.68M | Sell |
153,920
-465
| -0.3% | -$27.8K | 1.26% | 30 |
|
|
2013
Q2 | $7.92M | Buy |
+154,385
| New | +$8.05M | 1.17% | 29 |
|
Other funds holding GILD
VCM
VPM
Cannell & Spears's GILD Position: Q1 2026 in Review
Cannell & Spears increased its Gilead Sciences (GILD) stake by 0.19% in Q1 2026, buying an estimated $840 and bringing the position to 3,146 shares worth $438K. The position accounts for 0.01% of the portfolio, ranked #311.
Cannell & Spears first reported a position in GILD in Q2 2013 and has held it in 43 quarters since. The position peaked at $26.3M in Q2 2019. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Cannell & Spears held 3,146 shares of Gilead Sciences worth $438K as of Q1 2026.
- Cannell & Spears bought 6 Gilead Sciences shares in Q1 2026, an estimated $840.
- Gilead Sciences made up 0.01% of Cannell & Spears's portfolio in Q1 2026, its #311 holding.
- Cannell & Spears first reported a position in Gilead Sciences in Q2 2013 and has held it in 43 quarters since.
- Cannell & Spears's Gilead Sciences position peaked at $26.3M in Q2 2019.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Cannell & Spears's 13F filing for Q1 2026, filed 14 May 2026.